Clinical trials: Intestines
Metastatic Colorectal Cancer
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate the pharmacokinetic characteristics of…
- Trial name
- NCT03977090
- Testing
- Geptanolimab Injection, Fruquintinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Genor Biopharma Co., Ltd.
Crohn's Disease
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
- Trial name
- NCT01233960
- Testing
- Prochymal®
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Mesoblast, Inc.
Short Bowel Syndrome
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome.
- Trial name
- NCT05023382
- Testing
- Teduglutide
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Takeda
Erythema Migrans of Lyme Disease
Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).
- Trial name
- SUBLYME (NCT06451913)
- Testing
- Amoxicillin + Saccharomyces boulardii CNCM I-745, Stool samples, BSFS : Bristol Stool Form Scale
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- Biocodex
Crohn's Disease
Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
Protocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in Crohn's Disease Activity Index (CDAI) of at least 100 points) in Protocol 603.
- Trial name
- NCT00543374
- Testing
- PROCHYMAL adult human mesenchymal stem cells
- Where
- 58 sites in United States, Canada
- Volunteers
- 98 people
- Sponsor
- Mesoblast, Inc.
Ulcerative Colitis, Crohn's Disease
Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract.
- Trial name
- NCT06459297
- Where
- 14 sites in South Korea
- Volunteers
- 105 people
- Sponsor
- AbbVie
Colorectal Cancer
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal…
- Trial name
- NCT00497497
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
Population With Self-perceived Gastro-intestinal Sensitivity to Fibers
Tolerance Profile of Soluble Fibers in Individuals With Self-perceived GI Sensitivity to Fibers (Tarine)
The purpose of this study is to determine the optimal dose of soluble fibers that induces tolerable gastrointestinal symptoms.
- Trial name
- Tarine (NCT06877013)
- Testing
- Fiber's mix (among 4 doses)
- Where
- France
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Colonoscopy
Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
The purpose of this study is to compare the safety and efficacy of BLI4900 bowel preparation to an FDA-approved control as 2-day, split-dose bowel preparations prior to colonoscopy in adult patients.
- Trial name
- NCT04446299
- Testing
- Bowel Prep
- Where
- 25 sites in United States
- Volunteers
- 519 people
- Sponsor
- Braintree Laboratories
Gastrointestinal Diseases, Colorectal Cancer
Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System
The primary objective of this multicenter, prospective, randomized study is to evaluate the performance of Pure-Vu System in cleansing patients' colon who are indicated for a colonoscopy procedure using one of two different…
- Trial name
- NCT03493009
- Testing
- Pure-Vu System
- Volunteers
- healthy volunteers welcome
- Sponsor
- Motus GI Medical Technologies Ltd
Colorectal Cancer
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise.
- Trial name
- NCT03491709
- Testing
- anti-EGFR monoclonal antibody, Cetuximab injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
A03 - Digestive System, B03 - Bacteria
Fermented Dairy Product and Bifidobacterium Diversity (ThreeBees)
Bifidobacterium strains with potential health benefits can contribute to the gastrointestinal wellbeing. However, the ability of these strains to survive gastro-intestinal tract stress and their impact on gut microbiome remains…
- Trial name
- ThreeB (TB) (NCT06799364)
- Testing
- 28-days consumption of Product A in 45 to 60-year-old healthy subjects., 28-days consumption of Product B in 45 to 60-year-old healthy subjects., 28-days consumption of Control product in 45 to 60-year-old healthy subjects.
- Where
- 3 sites in France
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Crohn's Disease
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat Crohn's disease in patients with at least one perianal fistula.
- Trial name
- NCT00267709
- Testing
- Visilizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Facet Biotech
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer
This observational study is a follow-up study of protocol ML18280. Survival data of patients who took part in and concluded study ML18280 will be collected for up to 5 years after LPLV of ML18270.
- Trial name
- NCT01339832
- Where
- 5 sites in Switzerland
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Crohns Disease
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
- Trial name
- NCT04397263
- Testing
- Guselkumab
- Where
- 25 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Janssen Pharmaceutical K.K.
Colorectal Cancer
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with…
- Trial name
- NCT00284258
- Testing
- CPT-11 and TS-1, CPT-11, 5-FU and l-LV
- Where
- Japan
- Volunteers
- 426 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Human Intestinal Microbiome
Comparative Study of Great Ape-caretaker Microbiome
The SHAPES-Captivity study seeks to identify metagenomic components of the intestinal microbiome shared by human beings and captive great apes living in proximity and in direct, daily contact.
- Trial name
- SHAPES-CAP (NCT03282708)
- Testing
- Fresh stool collection
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Ulcerative Colitis
CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission
This dose comparison study, taking place at over 200 sites worldwide, will compare the dosing, safety and efficacy of an investigational medicine OPC-6535 to the dosing, safety and efficacy of Asacol ® in the maintenance of…
- Trial name
- NCT00092508
- Testing
- OPC-6535, Asacol®
- Where
- 26 sites in United States
- Volunteers
- 1,725 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
The study is designed to investigate efficacy and safety of KBL697 in patients with mild to moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment for ulcerative colitis.
- Trial name
- NCT04898348
- Testing
- KBL697
- Where
- Australia
- Sponsor
- KoBioLabs
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.